Literature DB >> 1964463

The use of immunoglobulin in bone marrow transplantation.

P J Tutschka.   

Abstract

The role of bone marrow transplantation is to restore lymphohematopoietic function of a recipient whose marrow has been destroyed, either by disease or by the preparative therapy employed in an attempt to eradicate the patient's lymphohematopoietic malignancy. The restoration of lymphohematopoietic function through the donor graft occurs in stages, requires several months, and is often not completed until 1 to 2 years after transplantation. These sequential steps of immuno-reconstitution are associated with a number of definable and predictable immune deficiencies and seem to be responsible for the pattern of complications that emerges after transplantation. Most of these complications are either the result of, or associated with, infections that also occur in an almost predictable pattern. In the various phases of immune deficiency following sequentially after transplantation, the humoral immune system is greatly affected, thus raising the possibility that passively administered antibodies in the form of immune globulin therapy might be beneficial in all phases of the marrow transplant procedure. This paper attempts to summarize the use of immune globulin preparations in clinical bone marrow transplantation, showing the rationale for and some of the results of therapeutic immune globulin administration.

Entities:  

Mesh:

Year:  1990        PMID: 1964463      PMCID: PMC7101739          DOI: 10.1007/bf00918696

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  9 in total

Review 1.  The role of microflora in development of graft-versus-host disease.

Authors:  M Pollard; C F Chang; K K Srivastava
Journal:  Transplant Proc       Date:  1976-12       Impact factor: 1.066

2.  Cytomegalovirus infection in bone marrow transplant recipients: use of intravenous gamma globulin as a prophylactic and therapeutic agent.

Authors:  N Kapoor; E A Copelan; P J Tutschka
Journal:  Transplant Proc       Date:  1989-02       Impact factor: 1.066

3.  The diagnostic, prophylactic, and therapeutic uses of monoclonal antibodies to human cytomegalovirus.

Authors:  D Emanuel; J Peppard; J Chehimi; U Hammerling; R O'Reilly
Journal:  Transplant Proc       Date:  1987-12       Impact factor: 1.066

4.  Oral administration of IgG in marrow transplant recipients.

Authors:  E A Copelan; T Bechtel; N C Featheringham; M M Grose; D D Sedmak; N Kapoor; P J Tutschka
Journal:  Drug Intell Clin Pharm       Date:  1988-11

5.  Infectious gastroenteritis in bone-marrow-transplant recipients.

Authors:  R H Yolken; C A Bishop; T R Townsend; E A Bolyard; J Bartlett; G W Santos; R Saral
Journal:  N Engl J Med       Date:  1982-04-29       Impact factor: 91.245

6.  Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen.

Authors:  P J Tutschka; E A Copelan; J P Klein
Journal:  Blood       Date:  1987-11       Impact factor: 22.113

7.  Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. Beneficial effect of a protective environment.

Authors:  R Storb; R L Prentice; C D Buckner; R A Clift; F Appelbaum; J Deeg; K Doney; J A Hansen; M Mason; J E Sanders; J Singer; K M Sullivan; R P Witherspoon; E D Thomas
Journal:  N Engl J Med       Date:  1983-02-10       Impact factor: 91.245

8.  Graft-versus-host disease and sialodacryoadenitis viral infection in bone marrow transplanted rats.

Authors:  K M Rossie; J F Sheridan; S W Barthold; P J Tutschka
Journal:  Transplantation       Date:  1988-06       Impact factor: 4.939

9.  Functional asplenia in patients with chronic graft-versus-host disease: concise communication.

Authors:  M A Al-Eid; P J Tutschka; H N Wagner; G W Santos; M F Tsan
Journal:  J Nucl Med       Date:  1983-12       Impact factor: 10.057

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.